Guess which All Ords ASX healthcare stock just surged 11% on FDA news

Investors are sending the ASX healthcare stock soaring on Monday.

| More on:
Two lab workers fist pump each other.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The All Ordinaries Index (ASX: XAO) is up 0.4% in late morning trade on Monday, with one ASX healthcare stock doing plenty of the heavy lifting.

The high-flying company in question is Silicon Valley-based EBR Systems Inc (ASX: EBR), which is focused on treating cardiac rhythm disease.

EBR Systems shares closed on Friday trading at $1.365. At the time of writing, they are 7.8% higher at $1.47 after leaping to an intraday high of $1.52, up 11.4%.

As you can see on the chart below, that sees the ASX healthcare stock up a very, well, healthy 138% over the past 12 months.

Created with Highcharts 11.4.3Ebr Systems PriceZoom1M3M6MYTD1Y5Y10YALLwww.fool.com.au

Here's what's spurring investor interest today.

ASX healthcare stock leaps on FDA update

Investors are bidding up the EBR Systems share price after the company, developing the world's only wireless cardiac pacing device for heart failure (WiSE System), announced that the US Food and Drug Administration (FDA) has scheduled the manufacturing Pre-Approval Inspection (PAI) to commence next week, on 14 January.

The ASX healthcare stock had previously anticipated that the PAI would start this week. However, management noted that the one-week delay won't impact the expected FDA regulatory approval timing, which was said to remain on track for the first quarter of calendar year 2025.

Commercial launch is then projected to take place later this year.

According to the release, the PAI's purpose is to confirm that EBR's manufacturing procedures comply with US quality system regulations and ensure that EBR can consistently produce devices that meet these approved specifications.

EBR reiterated that the FDA has previously said that the onsite Biomedical Monitoring (BIMO) audit is unlikely to be a requirement prior to final approval.

The Breakthrough Device designation for the WiSE System enables EBR to receive prioritised review and interactive communication with the FDA until the review process is completed.

The ASX healthcare stock initially released details of the FDA's review process on 30 September.

At the time, EBR Systems CEO John McCutcheon said:

We are delighted that our PMA application has progressed to substantive review by the FDA, effectively moving into the final stages of our regulatory timeline. The FDA moved quickly through this step, which could have taken up to 45 days.

This significant milestone brings us even closer to US commercialisation and to making available our life-changing WiSE technology to heart failure patients in need.

That announcement came shortly after the ASX healthcare stock secured $50 million in new funding. The company noted this provided it with a "cash runway" to get it through the FDA approval process, adding that the funds would also support it through early commercialisation and revenue growth.

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A hipster dude leaps in the air with glee, seeing positive news on his tablet.
Healthcare Shares

Which ASX 200 stock is jumping 11% on big news?

Investors are responding very positively to a big announcement.

Read more »

Senior woman using cpap machine to stop choking and snoring from obstructive sleep apnoea with bokeh and morning light background.
Healthcare Shares

Up more than 75% since October 2023 — are ResMed shares a buy, hold or sell?

ResMed shares have surged more than 75% since October 2023, but is it too late to buy? We break down…

Read more »

Stethoscope with a piggy bank in the middle.
Broker Notes

Australian health insurance: Does Macquarie prefer Medibank or NIB shares?

Medibank and NIB shares have both surged in 2025. Here’s what Macquarie expects now.

Read more »

Two brokers analysing stocks.
Healthcare Shares

Why does Macquarie think Fisher & Paykel shares are a buy?

Fisher & Paykel Healthcare Corporation Ltd (ASX: FPH) shares have been on form over the past 12 months. During this…

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Which small cap ASX share is jumping 10% on strong results

Investors have been bidding this stock higher today. But why?

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why Macquarie forecasts 30-50% upside for these ASX All Ords healthcare stocks

Macquarie updated its target price on these three ASX All Ords healthcare stocks.

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

Guess which ASX 200 stock is jumping 10% on big news

This stock is catching the eye with a strong gain on Thursday. But why?

Read more »

a young woman holds her hand to her ear and leans sideways as if to listen to something that's surprising her as her eyes and her mouth are wide open.
Healthcare Shares

Down 15% since January, are Cochlear shares now a buy?

Let's see what analysts are saying about this blue chip.

Read more »